Apobiologix's Bambevi (biosimilar- bevacizumab) Receives Health Canada Approval for Multiple Cancer Indications
Shots:
- Apobiologix expands its footprints in Canada with the approval of Bambevi + CT to treat colorectal- lung- brain and ovarian cancer
- The approval is coupled with well-established Apobiologix supportive care products that enable the company to transform access to affordable therapies in oncology and other indications
- In 2016- Apobiologix launched its first product- Grastofil (filgrastim) followed by the launch of Lapelga in 2019 in Canada. Additionally- Apobiologix is the first company to offer a portfolio of G-CSF biosimilars
| Ref: Newswire | Image: Biospace
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com